Another HDAC inhibitor, trichostatin A, increases the frequency of IL‐10- and TGF‐β‐producing CD5+CD1dhigh B cells in vitro and in vivo [121], suggesting that HDAC inhibitors might be potential agents for treating autoimmune diseases and transplant rejection. Here, HDAC9 is linked to autoimmune disease.